BNET Industries
Market Cap:$121.4B
Last Fiscal Year Sales:$32.4B
- Public
- CH
Dow Jones Description
Roche's focus is health. Roche Holding Ltd. (OTC: RHHVF (ADR) Swiss) was founded in 1896 and is headquartered in Basel, Switzerland. The company operates in two segments, which are pharmaceuticals and diagnostics. Its drugs include Accutane, Herceptin, Invirase, Rituxan, Rocephin, Tamiflu, and Xenical, among others. It owns 60% of Genentech and 51% of Chugai Pharmaceutical. The company has annual revenue of about $27 billion and employs about 68,000 people. In 2005, it sold its consumer healthcare division to Bayer, allowing it to focus on core business.In July 2005 the company acquired GlycArt Biotechnology AG, a privately owned Swiss biotech company that provides technology for enhancing the efficacy of antibodies will further strengthen Roche's expertise in therapeutic antibody research and development.
Board of Directors
DeAnne S. JuliusNumber of Employees 80,080
Peer Companies
NAICS Code In-Vitro Diagnostic Substance Manufacturing: 325413
Recent Events
-
UPDATE 2-US FDA panel rejects early use of Tarceva
-
UPDATE: Roche's New Diabetes Drug Works Better Than Byetta
-
Roche says 3Q sales up 9 per cent driven by cancer drugs, Tamiflu; raises full...
-
SurModics enters license and development agreement with Roche and Genentech
-
BRIEF-Roche launches new MagNA pure 96 system
-
Vivus CEO Ready To Roll Up Sleeves In Finding Qnexa Partner
-
Roche Holding names Soriot as head of pharma
-
Roche Holding names Soriot as head of pharma
-
Roche Holding names Soriot as head of pharma
-
Roche Holding names Soriot as head of pharma
-
Roche Holding names Soriot as head of pharma
-
Roche Holding names Soriot as head of pharma
-
Roche sees isolated cases of Tamiflu resistance
-
Roche Ups Guidance Amid Tamiflu Boost
News & Analysis
Filter by
roche holding ag - All News and Analysis
Drugmakers Pfizer, Roche Disappoint With Forecasts
BNET
- 2010-02-08
NEW YORK (Reuters UK) - Top global drugmakers Pfizer Inc PFE and Roche Holding AG ROG posted disappointing profits and gave lacklustre forecasts on Wednesday, sending their shares lower.The reports underscore a generally uninspiring results season for the pharmaceutical industry, which is being squeezed by the loss of patent protection...
Drugmakers Pfizer, Roche Disappoint With Forecasts
ReutersUK
- 2010-02-03
By Ransdell Pierson and Lewis KrauskopfNEW YORK (Reuters UK) - Top global drugmakers Pfizer Inc PFE and Roche Holding AG ROG posted disappointing profits and gave lacklustre forecasts on Wednesday, sending their shares lower.The reports underscore a generally uninspiring results season for the pharmaceutical industry, which is being squeezed by...
Roche - RoActemra: hoots mon!
BNET
- 2010-01-19
Roche's new rheumatoid arthritis drug RoActemra will be made available on the state health service in Scotland, despite being deemed too expensive by regulators in England. The Scottish Medicines Consortium, which decides on the cost-effectiveness of medicines, said it had accepted the drug for restricted use within the National...
US FDA approves Roche's Actemra for previously treated RA - update
BNET
- 2010-01-12
The US FDA has approved Roche's first-in-class IL-6-receptor inhibiting monoclonal antibody Actemra tocilizumab for the treatment of moderate-to-severely active rheumatoid arthritis RA in patients who are unresponsive to TNF inhibitors. The drug will be available in the US from January...
NICE Seeks More Data on Roche Arthritis Drug
BNET
- 2009-12-17
LONDON (Reuters UK) - Britain's cost-effectiveness watchdog said it was minded not to recommend Roche's new arthritis drug RoActemra on the state health service, but could change its mind if the drugmaker handed over more data. The National Institute for Health and Clinical Excellence NICE said on Wednesday it wanted...
Efficacy of Roche's Flu Drug Tamiflu In Doubt
BNET
- 2009-12-16
Allegations have surfaced that Swiss drug maker Roche Holding AG has mislead governments and physicians alike on the efficacy of its popular drug Tamiflu in preventing complications, such as hospitalization from pneumonia or death, in otherwise healthy people afflicted with the flu -- seasonal or the H1N1 swine flu pandemic....
Further doubts voiced on benefit of Tamiflu
BNET
- 2009-12-09
Fresh doubt has been thrown on the value of Roche's blockbuster antiviral flu drug Tamiflu. An academic article argued that a lack of good quality scientific data "undermined" claims that it prevented complications such as pneumonia. A review of clinical trials in the BMJ medical journal by the Cochrane Acute...
Some more on Tamiflu, influenza policy and drug regulation
BNET
- 2009-12-08
The BMJ has just published a cracking series of articles online, including a revised Cochrane Collaboration review, that throw out some hefty challenges to influenza policy makers, pharmaceutical companies, researchers, governments and drug regulators. The articles raise many questions about the evidence base that has been used to guide influenza...
Aegis Therapeutics and Roche Enter Into a License Agreement for ProTek(R) Stabilization
- 2009-12-01
Aegis Therapeutics LLC Aegis announced today that they have signed a License Agreement providing Roche access to Aegis' proprietary ProTek® stabilization technology. The ProTek® technology covers the use of specific excipients as stabilizers in certain manufacturing processes and formulations of protein-based therapeutics. Under the terms of the...
TriCore Evaluated Roche`s New MagNA Pure 96 Purification System for Research on Pathogenic Virus and Bacteria
- 2009-12-01
PENZBERG, Germany -- TriCore Reference Laboratories of Albuquerque, N.M., reported at a recent user meeting results of their research collaboration with Roche Applied ...
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Severin Schwan | Chief Executive Officer |
| William M. Burns | CEO, Roche Pharma |
| Erich Hunziker | CFO |
| Jonathan K.C. Knowles | Managing Director, Global Pharmaceutical Research |
| Roche Rolf D Schl | Managing Director, Partner |
| Rolf D Schl | Managing Director, Partner |
| Andres Greuter | Compliance Officer |
| Beatrice Weder | |
| Beatrice Weder di Mauro | |
| Berufliche Laufbahn | |
| Burkhard G Piper | |
| Dr Roche Severin Schwan | |
| Editiones Roche | |
| Eduard E Holdener | |
| Emil Frey Dir | |
| Ernst Peter Fischer | |
| Fr U here Mandate | |
| Fritz Gerber | |
| Gottlieb A. Keller | Secretary & Head, Corp Services, HR |
| Heino von Prondzynski | |
| Ian Massey | |
| James Childress | |
| Leiter der | |
| Leiter Therapiebereichs Des | |
| Lydia Mez | |
| Mina Michal | |
| Myrl Weinberg | |
| Okonomin beim Internationalen WAhrungsfonds | |
| Osamu Nagayama | |
| Peter Brabeck | |
| Ph D in Genetics | |
| Ph D in Genetik | |
| Pierre Jaccoud | |
| Prof Dr Roche Bruno Gehrig | |
| Robert B. Stein | |
| Robert Spreng | |
| Roche Burkhard G Piper | |
| Roche Genetics | |
| Roche Pierre Jaccoud | |
| Roche Sitemap | |
| Seite drucken | |
| Susan Jebb | |
| Werner Schreiber | |
| Ysbrand Portman |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| DeAnne S. Julius | Board of Directors |
| Dr Roche Gottlieb Keller | Chairman |
| Andre Hoffman | Board of Directors |
| Andre Hoffmann | Vice-Chairman of the Board |
| Andreas Oeri | Board of Directors |
| Brouno Gehring | Vice Chairman |
| Bruno Gehrig | Board of Directors |
| Peter Brabeck-Letmathe | Board of Directors |
| Rolf Hanggi | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| The Royal Institute of International Affairs | Chairman | Current |
| Roche Holding Ltd. | Board of Directors | Current |
| BP plc | Board of Directors | Current |
| University of California | Ph.D In Economics | Former |
| Iowa State University | Ph.D | Former |
| Iowa State University | Bsc | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Chief Executive Officer | Current |
| University of Innsbruck | Degree, Economics | Former |
| University of Innsbruck | Doctorate in Law | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | CEO, Roche Pharma | Current |
| Roche Products (Proprietary) Limited | President | Current |
| Chugai Pharmaceutical Co., Ltd. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | CFO | Current |
| F. Hoffmann-La Roche Ltd. | CFO | Current |
| Chugai Pharmaceutical Co., Ltd. | Board of Directors | Current |
| Genentech, Inc. | Board of Directors | Current |
| Holcim Ltd. | Board of Directors | Current |
| Diethelm Keller Holding Ltd. | Chief Executive Officer | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Managing Director, Global Pharmaceutical Research | Current |
| Genentech, Inc. | Head, Global Research | Current |
| Genentech, Inc. | Board of Directors | Current |
| Chugai Pharmaceutical Co., Ltd. | Board of Directors | Current |
| University of East Anglia | Honours Degree in Molecular Genetics | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Managing Director, Partner | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Managing Director, Partner | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Compliance Officer | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current | |
| Boehringer Mannheim | CEO | Former |
| Boehringer Mannheim | Sales Managers Industrial | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current | |
| The University of Kansas | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current | |
| University of Bern | Lawyer LL | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Diagnostics Corporation | Secretary | Current |
| Roche Diagnostics Corporation | Secretary | Current |
| Roche Diagnostics Corporation | Secretary | Current |
| Roche Holding Ltd. | Secretary & Head, Corp Services, HR | Current |
| Roche Holding Ltd. | Secretary & Head, Corp Services, HR | Current |
| Roche Holding Ltd. | Secretary & Head, Corp Services, HR | Current |
| Roche Holding Ltd. | Board of Directors | Current |
| Roche Holding Ltd. | Board of Directors | Current |
| Roche Holding Ltd. | Board of Directors | Current |
| Roche Diagnostics Corporation | Secretary | Former |
| Roche Diagnostics Corporation | Secretary | Former |
| Roche Diagnostics Corporation | Secretary | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current | |
| Alcon, Inc. | Vice Chairman | Current |
| Nestle S.A. | CEO | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current | |
| University of Bern | Doctorate in economics (Dr | Former |
Dr. Robert Stein currently serves on the President's Board of Advisors for Science and Innovation for the University of California , is a Member of the Board of Directors of Archemix, and Scientific Advisor to Takeda San Diego. Bob served as the Site President of the Palo Alto , California site of F. Hoffmann-La Roche Ltd from 2003 to 2006. Prior to joining Roche, Bob was the President and Chief Scientific Officer of Incyte Corporation from 2001 to 2003. Bob also served in various roles for Merck & Co., Ligand Pharmaceuticals Inc., the DuPont Merck Pharmaceutical Company and DuPont Pharmaceuticals Company, where he was Executive Vice President of Research and Preclinical Development from 1990 to 1996. Bob received degrees in biology and chemistry from Indiana University , where he was Phi Beta Kappa, and an M.D. and a Ph.D. in physiology and pharmacology from Duke University . Bob completed residency training and is board certified in anatomic and clinical pathology.
| Organization | Position | Status |
|---|---|---|
| Kinemed, Inc | Chief Executive Officer | Current |
| Roche Holding Ltd. | Current | |
| Kinemed, Inc | Member of The Board of Directors of Archemix, and Scientific Advisor | Current |
| Incyte Corporation | President | Former |
| F. Hoffmann-La Roche Ltd. | Site President | Former |
| Ligand Pharmaceuticals Incorporated | chief | Former |
| Incyte Corporation | Chief Scientific Officer | Former |
| Ligand Pharmaceuticals Incorporated | senior vice president | Former |
| Roche | Former | |
| Geron Corporation | Board of Directors | Former |
| Archemix Corp | Board of Directors | Current |
| diaDexus, Inc. | Board of Directors | Former |
| Duke University | M.D. | Former |
| Duke University | Degrees In Biology | Former |
| Indiana University | Degrees In Biology | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current | |
| Roche Holding Ltd. | Current | |
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current | |
| Boehringer Mannheim | CEO | Former |
| Boehringer Mannheim | Regional Sales Manager | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current | |
| Rs-R | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current | |
| Alcon, Inc. | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Chairman | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Living Planet Management Company | Chairman | Current |
| Roche Holding Ltd. | Vice-Chairman of the Board | Current |
| Givaudan S.A. | Vice Chairman | Current |
| Roche Holding Ltd. | Member | Current |
| Nestle Uk Ltd | Brand Manager | Former |
| Givaudan S.A. | Board of Directors | Former |
| INSEAD | Masters of Business Administration | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Board of Directors | Current |
| University of Basel | Medical Studies | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Vice Chairman | Current |
| Roche Holding Ltd. | Vice Chairman | Current |
| Roche Holding Ltd. | Vice Chairman | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Vice Chairman | Current |
| Roche Holding Ltd. | Board of Directors | Current |
| University of Bern | Doctorate in economics (Dr | Former |
Peter Brabeck-Letmathe has been a member of the Board since 1997 and served as Vice-Chairman from 2000 to 2005 and since 2008. Since 2008 he has also served on the Chairman's and Governance Committee and the Compensation Committee. On both of these committees he has already served in the past, namely from 2003 to 2005 and 2000 to 2005, respectively. His term as a member of the Board expires at the AGM in 2011. The Board has determined him to be independent under the Group’s independence standards. Peter Brabeck-Letmathe studied Economics at the University of World Trade in Vienna. After graduation in 1968, he joined Nestlé’s sales operations in Austria. His career at Nestlé includes a variety of assignments in several European countries as well as in Latin America. Since 1987, he has been based at Nestlé’s headquarters in Vevey. Since 1997, Mr. Brabeck-Letmathe has served as the Chief Executive Officer of Nestlé and as a member of Nestlé’s Board of Directors. In 2005, Mr. Brabeck-Letmathe was appointed Chairman of the Board of Directors of Nestlé. As of April 10, 2008 he has retired from his function as Chief Executive Officer of Nestlé. Mr. Brabeck is a member of the Boards of Directors of L’Oréal SA, Paris (since 1997) and Roche Holding SA, Basel (since 2000). He is also a member of the Foundation Board of the World Economic Forum and a member of the European Round Table of Industrialists.
| Organization | Position | Status |
|---|---|---|
| Credit Suisse Group | Vice Chairman | Current |
| Winterthur Schweizerische Versicherungs Gesellschaft | Vice Chairman | Current |
| Credit Suisse Group | Board of Directors | Current |
| Nestle S.A. | Board of Directors | Current |
| L'Oreal S.A. | Board of Directors | Current |
| Roche Holding Ltd. | Board of Directors | Current |
| World Economic Forum | Member, Foundation Board | Current |
| Nestle S.A. | Chief Executive Officer | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Board of Directors | Current |
| Nestle S.A. | Second Vice Chairman | Current |
| Nestle S.A. | Second Vice Chairman | Current |
| Zurich Insurance Company | Deputy Chief Executive Officer | Former |
| Zurich Insurance Company | Member | Former |
| Zurich Insurance | Member | Former |
| Nestle S.A. | Vice-Chairman | Former |
| Volume | 90,922 |
| Shares Outstanding | 2.8B |
| Market Cap | 121.4B |
| Year High | 44.0 |
| Year Low | 9.999 |
| Earnings Per Share | 2.370 |
| P/E Ratio | 18. |
| Dividend | 0.665 |
| Yield | 1.53 |
Industry Transcripts by Seeking Alpha
-
Biogen Idec, Inc. Q4 2009 Earnings Call Transcript
on Feb 09, 2010about BIIB
-
Charles River Laboratories International Inc. Q4 2009 Earnings Call Transcript
on Feb 09, 2010about CRL
-
Ligand Pharmaceuticals Incorporated Q4 2009 Earnings Call Transcript
on Feb 09, 2010about LGND
-
Vertex Pharmaceuticals Inc. Q4 2009 Earnings Call Transcript
on Feb 04, 2010about VRTX
-
Alkermes, Inc. F3Q10 (Qtr End 12/31/09) Earnings Call Transcript
on Feb 04, 2010about ALKS
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Efficacy of Roche's Flu Drug Tamiflu In Doubt 3 votes
- The 5 Worst Drug Companies of 2009 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- 2010 FDA Approvals Could Lead to Launch of Eight Blockbuster Biotech Drugs 3 votes
